McKesson's most recent trend suggests a bullish bias. One trading opportunity on McKesson is a Bull Put Spread using a strike $160.00 short put and a strike $150.00 long put offers a potential 14.29% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $160.00 by expiration. The full premium credit of $1.25 would be kept by the premium seller. The risk of $8.75 would be incurred if the stock dropped below the $150.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for McKesson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for McKesson is bullish.
The RSI indicator is at 75.13 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for McKesson
Is McKesson (MCK) a Great Value Stock Right Now?
Wed, 19 Feb 2020 16:50:04 +0000
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Drug Distributor Stocks in Focus on Opioid Settlement News
Tue, 18 Feb 2020 13:46:08 +0000
Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.
Andreas Halvorsen's Top 5 Buys in the 4th Quarter
Fri, 14 Feb 2020 20:29:43 +0000
Viking leader releases quarterly portfolio Continue reading…
U.S. States Reject Drug Wholesalers' Opioid-Settlement Offer
Fri, 14 Feb 2020 16:46:00 +0000
The 21 U.S. state attorneys general who sued opioid makers rejected a settlement offer of $18 billion from three drugmakers that were looking to end the litigation against them, a media report says.
MCK vs. COO: Which Stock Should Value Investors Buy Now?
Fri, 14 Feb 2020 16:40:04 +0000
MCK vs. COO: Which Stock Is the Better Value Option?
Also on Market Tamer…
Follow Us on Facebook